293780 Stock Chart & Stats
₩4340.00
-₩145.00(-3.23%)
―
--
Day’s Range― - ―
52-Week Range₩3,870.00 - ₩10,890.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.34K
Market Cap
₩126.00B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,093,405
10 Day Avg. Volume53,848
30 Day Avg. Volume91,345
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
293780 FAQ
What was Aptabio Therapeutics, Inc.’s price range in the past 12 months?
Aptabio Therapeutics, Inc. lowest stock price was ₩3870.00 and its highest was ₩10890.00 in the past 12 months.
What is Aptabio Therapeutics, Inc.’s market cap?
Aptabio Therapeutics, Inc.’s market cap is ₩126.00B.
When is Aptabio Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aptabio Therapeutics, Inc.’s earnings last quarter?
Aptabio Therapeutics, Inc. released its earnings results on May 15, 2026. The company reported -₩229.406 earnings per share for the quarter, missing the consensus estimate of N/A by -₩229.406.
Is Aptabio Therapeutics, Inc. overvalued?
According to Wall Street analysts Aptabio Therapeutics, Inc.’s price is currently Undervalued.
Does Aptabio Therapeutics, Inc. pay dividends?
Aptabio Therapeutics, Inc. does not currently pay dividends.
What is Aptabio Therapeutics, Inc.’s EPS estimate?
Aptabio Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptabio Therapeutics, Inc. have?
Aptabio Therapeutics, Inc. has 28,093,405 shares outstanding.
What happened to Aptabio Therapeutics, Inc.’s price movement after its last earnings report?
Aptabio Therapeutics, Inc. reported an EPS of -₩229.406 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.563%.
Which hedge fund is a major shareholder of Aptabio Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KR:293780
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Macrogen, Inc.
―
ISU Abxis Co., Ltd.
―
Genexine, Inc.
―
Keeps Biopharma Inc.
―
ViGenCell, Inc.
―